|Biotech Due Diligence||
A favorite pastime here at BiotechDueDiligence is combing through all those SEC filings that are submitted between 4 PM and 5:30 PM on Friday before a holiday weekend. This time was especially tricky because of the volume of 13-G ownership submissions that came in on the same day. I have included some of the highlights below.
Living With Cancer: A Broken Covenant With Patients
Susan Gubar (New York Times)
On clinical trial data disclosures
Drug Pricing: Lack of Transparency and Trust Compound the Problem
Stewart Lyman (Lyman Biopharma Blog)
Big Pharma’s worst nightmare
Jamie Love has spent years battling global drug companies, unshakable in his belief that even the world’s poorest people should have access to life-saving medicines. Is it time that our own government listened to him?
Sarah Boseley (The Guardian)
Commentary on this article "Compassion, Drug Prices and Money"
Derek Lowe (In the Pipeline)
How a Medical Mystery in Brazil Led Doctors to Zika
Donald McNeil Jr., Simon Romero and Sabrina Tavernise (New York Times)
Who's on board with Twitter's 10,000-character limit? Pharma brand managers
Emily Wasserman (FiercePharmaMarketing)
I am excited to announce the launch of a new feature here at BiotechDueDIligence. To date, one aspect of the biotechnology industry that has lacked coverage on the site is medical devices. Going forward that will change, as new contributor Chris Ware comes on board to fill this gap and broaden the reach and appeal of BiotechDueDiligence.
For your pre-Super Bowl enjoyment, @BioDueDIligence and @23aloha present the latest installment of the Biotech Tweets of the Week. This edition features:
Biotech Tweets of the Week (February 1-5, 2016)
$AAVL $ACAD $ADAP $AGN $AVXS $AXON $BGNE $BLUE $CEMP $EDIT $GILD $ICPT $JUNO $KITE $ONCE $PETX $PFE $PTI $SRPT $VRTX $VRX $XBI $IBB
FDA, biosimilars, drug pricing, opioids, biotech market sentiment, cancer moon shot, CRISPR, IPOs
Your support is greatly appreciated